No Data
No Data
Optimistic Buy Rating for Alto Neuroscience Backed by Strategic Clinical Trials and Promising Data
Institutional Investors of Alto Neuroscience, Inc. (NYSE:ANRO) Must Be Disappointed After Last Week's 26% Drop
IPO Roundup: Pershing Square, Actuate Therapeutics and More
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)
Express News | Alto Neuroscience Receives Funding Award From Wellcome Trust to Accelerate Development of Alto-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
No Data